About Upstream Bio, Inc.
https://upstreambio.comUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor.
CEO
E. Rand Sutherland M.P.H., MPH
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 94
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
FMR LLC
Shares:8.09M
Value:$261.19M
ORBIMED ADVISORS LLC
Shares:5.69M
Value:$183.9M
DECHENG CAPITAL LLC
Shares:3.29M
Value:$106.11M
Summary
Showing Top 3 of 98
About Upstream Bio, Inc.
https://upstreambio.comUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $683K ▼ | $38.49M ▼ | $-33.75M ▲ | -4.94K% ▼ | $-0.63 ▲ | $-33.72M ▲ |
| Q2-2025 | $937K ▲ | $45.28M ▲ | $-39.97M ▼ | -4.27K% ▲ | $-0.74 ▼ | $-44.3M ▼ |
| Q1-2025 | $566K ▼ | $32.58M ▲ | $-27.27M ▼ | -4.82K% ▼ | $-0.51 ▼ | $-31.97M ▼ |
| Q4-2024 | $613K ▲ | $26.93M ▲ | $-21.24M ▼ | -3.47K% ▼ | $-0.41 | $-26.27M ▼ |
| Q3-2024 | $607K | $19.5M | $-15.99M | -2.63K% | $-0.41 | $-18.88M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $372.43M ▼ | $391.19M ▼ | $12.61M ▲ | $378.58M ▼ |
| Q2-2025 | $393.58M ▼ | $420.52M ▼ | $11.78M ▲ | $408.74M ▼ |
| Q1-2025 | $431.38M ▼ | $456.17M ▼ | $10.56M ▼ | $445.61M ▼ |
| Q4-2024 | $470.45M ▲ | $481.72M ▲ | $11.87M ▼ | $469.85M ▲ |
| Q3-2024 | $220.66M | $232.7M | $393.01M | $-160.31M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-33.75M ▲ | $-22.24M ▲ | $48.19M ▲ | $760K ▲ | $26.71M ▲ | $-22.19M ▲ |
| Q2-2025 | $-39.97M ▼ | $-39.24M ▲ | $12.77M ▲ | $612K ▲ | $-25.85M ▲ | $-39.29M ▲ |
| Q1-2025 | $-27.27M ▼ | $-41.16M ▼ | $-213.38M ▼ | $-34K ▼ | $-254.58M ▼ | $-41.16M ▼ |
| Q4-2024 | $-21.24M ▼ | $-19.61M ▼ | $41.91M ▲ | $270.65M ▲ | $292.94M ▲ | $-19.8M ▼ |
| Q3-2024 | $-15.99M | $-13.96M | $1.41M | $-1.64M | $-14.19M | $-14.29M |
CEO
E. Rand Sutherland M.P.H., MPH
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 94
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
FMR LLC
Shares:8.09M
Value:$261.19M
ORBIMED ADVISORS LLC
Shares:5.69M
Value:$183.9M
DECHENG CAPITAL LLC
Shares:3.29M
Value:$106.11M
Summary
Showing Top 3 of 98